Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

 

Open label evaluation of potential interaction of F901318 with cytochrome P450 3A4 using midazolam as a probe. Twenty healthy male subjects will participate

Condition Intervention Phase
Invasive Aspergillosis Drug: Midazolam with F901318 Phase 1
Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Study in Healthy Volunteers to Evaluate the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Antifungal name: 

Date of article/Start date of trial: 

Monday, April 4, 2016

Trial phase: 

Phase 1

ClinicalTrials.gov ID: 

NCT02680808

Trial status: 

Active
New antifungal drugs